# Instil Bio (TIL) — News

TIL · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/til/news

## Recent headlines

- [CPBIO renewal of continuing connected transactions, notice of special general meeting](https://www.ainvest.com/news/cpbio-renewal-continuing-connected-transactions-notice-special-general-meeting-2610-19) — AInvest Wire, Oct 13, 2026
  Cancer Prevention & Biotechnology Limited (CPBIO) has announced the renewal of its continuing connected transactions, as disclosed in a recent regulatory filing. The company has also issued a notice of a special general meeting (SGM) to be held on October 30, 2026, for shareholders to consider and…
- [CPBIO renewal of continuing connected transactions, notice of special general meeting](https://www.ainvest.com/news/cpbio-renewal-continuing-connected-transactions-notice-special-general-meeting-2610) — AInvest Wire, Oct 13, 2026
- [Info Edge Board OKs ~INR 1B investment in unit 5IHL](https://www.ainvest.com/news/info-edge-board-oks-inr-1b-investment-unit-5ihl-2610) — AInvest Wire, Oct 13, 2026
  Info Edge (India) Limited has approved an investment of approximately INR 1 billion in its subsidiary, 5IHL, as part of its strategic capital allocation plans. The investment, approved by the company’s board of directors, is intended to support the subsidiary’s operational requirements and to…
- [ImmuneOnco Biopharmaceuticals (Shanghai) - stock exchange finds ImmuneOnco loan not on normal commercial terms](https://www.ainvest.com/news/immuneonco-biopharmaceuticals-shanghai-stock-exchange-finds-immuneonco-loan-normal-commercial-terms-2607) — AInvest Wire, Jul 2, 2026
  ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (01541.HK) has recently been notified by the Hong Kong Stock Exchange that loan arrangements were not made on normal commercial terms, raising regulatory concerns. This development comes amid ongoing collaboration and financial progress in the company’s…
- [Allogene Therapeutics names Zachary Roberts as CEO](https://www.ainvest.com/news/allogene-therapeutics-names-zachary-roberts-ceo-2605) — AInvest Wire, May 28, 2026
  Allogene Therapeutics, Inc. (Nasdaq: ALLO) has appointed Zachary J. Roberts, M.D., Ph.D., as Executive Vice President of Research and Development, a role that includes oversight of the company’s clinical and pre-clinical programs. Dr. Roberts succeeds Rafael Amado, M.D., who has stepped down to…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).